Figure 7.

The p38 inhibitor SB203580 attenuated cell cycle arrest. HepG2 cells were pretreated with the indicated concentrations of SB203580 for 1 h and then treated with various concentrations of telekin (0, 5, 10, and 15 μmol/L) for 24 h. (A) SB203580 treatment decreased the percentage of cells in the G₂/M phase from 50.88% to 26.56% (2.5 μmol/L SB203580) and 17.17% (5 μmol/L SB203580) after 24-h treatment with 15 μmol/L telekin. Inhibiting the activity of p38 attenuated the effect of telekin on cell cycle regulation. (B) The corresponding histograms were obtained from triplicate experiments and are presented at the bottom of the figure. ^bP<0.05, ^cP<0.01 vs 0 μmol/L SB203580 group.